Search Results for "Narcolepsy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Narcolepsy. Results 11 to 17 of 17 total matches.

Daridorexant (Quviviq) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
, sustains wakefulness. Loss of orexin signaling has been associated with narcolepsy. Like suvorexant ...
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):107-10 |  Show IntroductionHide Introduction

New Indications for Modafinil (Provigil)

   
The Medical Letter on Drugs and Therapeutics • Apr 26, 2004  (Issue 1181)
with narcolepsy (Medical Letter 1999; 41:30), has now also been approved for treatment of patients with excessive ...
Modafinil (Provigil - Cephalon; Alertec - Draxis in Canada), first approved by the FDA in 1999 for treatment of excessive daytime sleepiness associated with narcolepsy (Medical Letter 1999; 41:30), has now also been approved for treatment of patients with excessive sleepiness due to obstructive sleep apnea/hypopnea syndrome (OSAHS) or shift work sleep disorder (SWSD) (DSM-IV, text revision, Washington, DC: American Psychiatric Association, 2000, page 622).
Med Lett Drugs Ther. 2004 Apr 26;46(1181):34-5 |  Show IntroductionHide Introduction

Racemic Amphetamine Sulfate (Evekeo) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Sep 28, 2015  (Issue 1478)
. It was also approved for treatment of narcolepsy in patients ≥6 years old and for short-term treatment ...
The FDA has approved racemic amphetamine sulfate (Evekeo – Arbor) for oral treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥3 years old. It was also approved for treatment of narcolepsy in patients ≥6 years old and for short-term treatment of obesity in patients ≥12 years old.
Med Lett Drugs Ther. 2015 Sep 28;57(1478):137-8 |  Show IntroductionHide Introduction

Suvorexant (Belsomra) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
with narcolepsy, which is characterized by excessive daytime sleepiness, cataplexy, hypnagogic and hypnopompic ...
The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):29-31 |  Show IntroductionHide Introduction

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
signaling has been associated with narcolepsy; orexin receptor antagonists are contraindicated for use ...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6   doi:10.58347/tml.2023.1667a |  Show IntroductionHide Introduction

Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
for use in patients with narcolepsy Should be administered with caution in patients with compromised ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10   doi:10.58347/tml.2023.1667b |  Show IntroductionHide Introduction

Drugs That Cause Sexual Dysfunction: An Update

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 1992  (Issue 876)
of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med, 285:987, 1971; R Christenson, MAOIs ...
Many commonly used drugs can interfere with sexual function in both men and women, causing loss of libido, interfering with erection or ejaculation in men, and delaying or preventing orgasm in women. Drug-related effects on sexual function may be difficult to distinguish from the effects of depression or disease, but most are reversible when drug use is stopped and sometimes when dosage is decreased. Since many patients are reluctant to talk about sexual difficulties, physicians may wish to ask about the possibility of drug-induced sexual dysfunction, particularly when they have...
Med Lett Drugs Ther. 1992 Aug 7;34(876):73-8 |  Show IntroductionHide Introduction